PRL-2903

PRL-2903 is a selective **somatostatin receptor type 2 (SSTR2) antagonist**. It is a peptide compound studied primarily in preclinical models for its ability to increase glucagon secretion by antagonizing somatostatin-mediated inhibition of pancreatic α-cells. In type 1 and type 2 diabetes models, PRL-2903 has been shown to enhance the counterregulatory glucagon response during hypoglycemic events, improving glucose recovery and potentially reducing hypoglycemia risk. PRL-2903 has also been shown to increase gastric acid secretion via SSTR2 antagonism, reflecting its activity on somatostatin-regulated systems. Administration methods explored include intravenous, subcutaneous, and transdermal microneedle patches. Though pharmacologically active, PRL-2903 is primarily a research tool and precursor to newer SSTR2 antagonists like ZT-01, which have entered clinical development[1][3][5][6][7].